Wellington Management Group
PRLD icon

Wellington Management Group’s Prelude Therapeutics PRLD Stock Holding History

Wellington Management Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,703
Closed -$503K – 1993
2020
Q3 		$503K Buy
+16,703
New +$472K ﹤0.01% 1704

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group's PRLD Position: Q4 2020 in Review

Wellington Management Group sold out of Prelude Therapeutics (PRLD) in Q4 2020, closing a stake of 16,703 shares — an estimated $503K sold.

Wellington Management Group first reported a position in PRLD in Q3 2020 and held it in 1 quarter. The position peaked at $503K in Q3 2020. 51 funds tracked by Wall St. Rank hold PRLD as of Q4 2020.

  • Wellington Management Group reported no remaining Prelude Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wellington Management Group sold 16,703 Prelude Therapeutics shares in Q4 2020, an estimated $503K.
  • Wellington Management Group first reported a position in Prelude Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wellington Management Group's Prelude Therapeutics position peaked at $503K in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2020.

Based on Wellington Management Group's 13F filing for Q4 2020, filed 12 Feb 2021.